Search:

Login | Subscribe

Home > Companies > Henderson Morley

Price	Market	Sector	Market Cap
0.70p (0.00p) 0.00%	AIM	Medicine and Biotech Research	£4.03m

Add to company folder | Print

Related Companies

AGY	16.75p	-1.47%
APH	5.88p	0.00%
AZH	p
BBI	p
CEN	p
CBF	5.00p	0.00%
COT	150.00p	-0.99%
CRX	3.25p	0.00%
CYX	p
LAC	p
EVC	25.50p	-0.97%
FUL	2.75p	0.00%
FUM	41.25p	0.00%
GMX	3.50p	0.00%
GNI	p
GWP	41.00p	7.89%
MLR	p
MMG	12.25p	0.00%
MPM	19.50p	0.00%

Commentary

Developer of herpes medication

Recent Articles

Carp deal cheers Henderson	22/05/2008
Herpes group for sale	29/01/2008
Herpes group fishes for funds	02/02/2007
Licensing talks lift Henderson Morley	12/01/2007
GCI grabs research gong	06/11/2006
Henderson loses £0.8m	14/07/2006
Ringing the changes at Monstermob	16/06/2006
Runners and riders in the medical stakes	10/04/2006
Results frenzy feeds AIM	24/03/2006
Henderson in partnership talks	16/03/2006
More

Recent Announcements

Director Shareholding	25/07/2008
Directors' Shareholding	23/07/2008
Directors' Shareholding	16/07/2008
Fish vaccine adjuvant develop	07/07/2008
Holding(s) in Company	09/06/2008
Trading Update - Replacement	22/05/2008
Trading Update	22/05/2008
Schering-Plough Agreement	14/04/2008
Issue of Equity	14/04/2008
Collaborative Agreement	26/03/2008
More

Articles from the Sector

Source BioScience plans restructure	28/08/2008
Asterand slashes interim loss	27/08/2008
ProStrakan targets USA	21/08/2008
Proximagen	18/08/2008
Chi-Med bullish despite interim losses	06/08/2008
Pharmaceuticals & biotechnology	04/08/2008
PuriCore seeks £10m	31/07/2008
Summit	25/07/2008
Axis-Shield wins China patent	21/07/2008
Concateno – niche market, nice margins	30/06/2008
More

Financial History

Financial Year End	30/04/2003	30/04/2004	30/04/2005	30/04/2006	30/04/2007
Currency	GBP	GBP	GBP	GBP	GBP
Turnover	0.01	0.01	0.01	0.00	0.02
Operating Profit	-0.68	-0.77	-0.86	-0.80	-0.98
Pretax Profit	-0.68	-0.77	-0.85	-0.78	-0.94
Earnings After Tax	-0.64	-0.71	-0.78	-0.71	-0.90
Profit Available For Dividend	0.00	0.00	0.00	0.00	0.00
Ordinary Dividends	0.00	0.00	0.00	0.00	0.00
Retained Profit	-0.64	-0.71	0.00	-0.71	-0.90
Shareholders Funds	0.25	0.31	0.88	0.41	1.68
Net Current Assets	0.02	0.10	0.72	0.27	1.52
Adjusted Earnings Per Share Undiluted	-0.40	-0.36	-0.27	-0.20	-0.20
Adj Earnings Per Share	-0.40	-0.36	-0.27	-0.20	-0.20
Dividend Per Share	0.00	0.00	0.00	0.00	0.00

Chart

Click here for interactive charting

Company Details
Address	Metropolitan House, 2 Salisbury Road, Mosely, Birmingham, B13 8JS
Telephone	0121 442 4600
Fax	0121 442 4611
Executives
Executive Chairman	Andrew Knight (15.00% holding)
Chief Executive	Ian Pardoe (9.70% holding)
Finance Director	Christopher Pate (0.00% holding)
Director	James Hill (1.10% holding)
Main Shareholders
	Barclays: 6.6% Michael P Dunne: 6.1% Billam AG: 4.8%
Advisers
Nominated Adviser	Brewin Dolphin Securities
Nominated Broker	Hybridan
Solicitors	Wragge & Co
Auditors	Moore Stephens
Registrar	Neville Registrars

Commentary
Developer of herpes medication
Company Data
Code	HML
Sedol	GB00307112
Shares In Issue	575.262 m
Indices	Aim
Entry on AIM	11/09/2001
Interim Results	Jan
Final Results	Sep
Year End	Apr
Accounts Due	Aug
Int div payment	n/a
Fin div payment	n/a
Int net div per share	nil
Fin net div per share	nil
Probable CGT relief	Yes